Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist

Introduction  Prehospital therapy of ST-elevation myocardial infarction (STEMI) with αIIbβ3 antagonists improves clinical outcomes, but they are difficult to use in prehospital settings. RUC-4 is a novel αIIbβ3 antagonist being developed for prehospital therapy of STEMI that rapidly achieves high-gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentur, Ohad S., Li, Jihong, Jiang, Caroline S., Martin, Linda H., Kereiakes, Dean J., Coller, Barry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478527/
https://www.ncbi.nlm.nih.gov/pubmed/34604694
http://dx.doi.org/10.1055/s-0041-1732343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478527/
https://www.ncbi.nlm.nih.gov/pubmed/34604694
http://dx.doi.org/10.1055/s-0041-1732343

Ejemplares similares